

APC anti-human CD32B/C

Catalog # / 2591515 / 25 tests
Size: 2591520 / 100 tests

Clone: S18005H

Isotype: Mouse IgG1, κ


Immunogen: Recombinant Human Fc gamma RIIB/C (CD32b/c) Protein

Reactivity: Human

Preparation: The antibody was purified by affinity chromatography and conjugated with APC under optimal conditions.

Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA (origin USA)

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with CD19 Alexa Fluor® 488 and CD 32B/C (clone S18005H) APC (left) or mouse IgG1, κ APC isotype control (right).

Applications:

Applications: Flow Cytometry

Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ L per million cells in 100 μ L staining volume or 5 μ L per 100 μ L of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes: As the extracellular region of CD32B and CD32C are identical, this Ab recognizes both isoforms. Does not crossreact with CD32A.

Description: CD32B/C (FCGR2B/C) is a 40 kDa, type I transmembrane protein, member of the Ig superfamily; the cytoplasmic tail contains an immunoreceptor tyrosine-based inhibition motif (ITIM). CD32B/C is the low affinity receptor for monomeric IgG but also bind IgG complexes. CD32B/C is expressed on B cells, subsets of monocytes, macrophages and granulocytes, platelets, mast cells, and is a negative regulator of cell activation, proliferation, endocytosis, phagocytosis, and degranulation.

- Antigen References:**
1. Bruhns P, et al. 2009. *Blood*. 113: 3716.
 2. Bewarder N, et al. 1996. *Mol Cell Biol*. 16: 4735.
 3. Descours B, et al. 2017. *Nature*. 543: 564.
 4. Tomiyama Y, et al. 1992. *Blood*. 80: 2261.
 5. Indik Z, et al. 1991. *J Clin Invest*. 88: 1766.
 6. Ramsland PA, et al. 2011. *J Immunol*. 187: 3208.
 7. Hogarth PM and Pietersz GA. 2012. *Nat Rev Drug Discov*. 11: 311.
 8. Bournazos S, et al. 2009. *J Immunol*. 182: 8026.
 9. Maxwell KF, et al. 1999. *Nat Struct Biol*. 6: 437.
 10. Sandilands GP, et al. 1997. *Immunology*. 91: 204.
 11. Ghazizadeh S, et al. 1994. *J Biol Chem*. 269: 8878.
 12. Gillis C, et al. 2014. *Front Immunol*. 5: 254.